Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.
Here’s a number worth sitting with: an estimated 99% of the chemical diversity found in nature has never been properly studied, because isolating and testing individual compounds from plants, microbes, and the human body has historically been too slow and expensive to bother. Enveda, a Colorado-based biotech, has built its entire platform around the bet that AI can finally make that chemistry readable, and worth reading.
On 23 September, Enveda announced it had closed a $311 million Series E round, led by Catalio Capital Management, bringing its total capital raised since founding to more than $845 million [1]. The round drew a notably broad investor base, from healthcare specialists like T. Rowe Price Investment Management and Surveyor Capital to tech-focused funds like ICONIQ and Lightspeed, alongside a sovereign wealth fund and existing backers including Baillie Gifford and Lux Capital.
An engine for one of pharma’s biggest unmet needs
Enveda’s platform, called PRISM, doesn’t design molecules from scratch the way a lot of AI drug-discovery tools do. Instead, it identifies compounds that already exist in nature, predicts their structure from mass spectrometry data, and ranks them by therapeutic potential before Enveda’s chemists refine the best candidates into oral medicines. Since 2019, that approach has produced 17 development candidates, three of which are now in human trials.
The one likely to matter most for longevity watchers is ENV-308, a molecule inspired by one the body naturally releases during intense exercise. It’s being developed to help people maintain weight loss and metabolic health after they stop taking GLP-1 medications like semaglutide, a real and growing problem as millions of patients cycle on and off those drugs. In an 88-person trial of healthy volunteers, ENV-308 was well tolerated, with an unusually clean gastrointestinal side-effect profile. That matters because GI side effects are one of the most common reasons people quit GLP-1 treatment in the first place. The trial also showed ENV-308 lowers circulating leptin, a hormone that signals how much energy the body has stored, an early sign the drug is reaching the biology researchers expect based on animal studies.
Enveda’s other clinical-stage medicine with 2026 data, ENV-294, targets atopic dermatitis and asthma and showed an 85% average improvement in eczema severity after 42 days in an early study. It’s a strong readout in its own right, though the metabolic health story is the one with the more direct line back to longevity: helping the body hold onto the benefits of weight loss, rather than losing them once medication stops, speaks to sustaining healthspan gains rather than chasing them repeatedly.
Viswa Colluru, Enveda’s founder and CEO, described the round as validation of a contrarian premise.
“We started Enveda on a different premise: the most reliable source of new medicines is the chemistry that living things have been refining for billions of years, and AI finally lets us read it,” he said. “Two novel molecules from that approach have now shown their early potential in people.”
Alex Gorsky, a general partner at ICONIQ and former CEO of Johnson & Johnson, framed the round as a bet on the platform, not just the pipeline.
“The rate of pipeline progression and early clinical data suggest this approach is working, and we believe this could represent an important milestone for patients and more broadly in healthcare,” he said.
Enveda says the new capital will push ENV-294 and ENV-308 into later-stage trials and new indications, advance a third candidate, ENV-6946, through mid-phase testing, and fund additional trials for other inflammatory and metabolic conditions. It’s also scaling the automated lab that feeds PRISM new data.
More on ENV-294 is expected at the European Academy of Dermatology and Venereology Congress on 1 October, but for anyone tracking the metabolic health space, ENV-308’s next data readout is the one to watch.
